SEC Filing Summary: Nukkleus Inc. (NUKK)
Business Context and Reporting Period
This Form 8-K, dated December 3, 2024, reports on Nukkleus Inc. (NUKK), a Delaware corporation listed on The Nasdaq Stock Market. The filing details the entry into a Standby Equity Purchase Agreement (SEPA) and the issuance of convertible promissory notes to secure liquidity. The company is currently an emerging growth company.
Key Financial Metrics and Capital Structure
- SEPA Capacity: The company has the right to sell up to $10 million of common stock to YA II PN, LTD (the Investor) over the term of the agreement.
- Convertible Notes (Pre-Paid Advance): An aggregate principal amount of $2.0 million in convertible notes was agreed upon.
- Initial Funding: The first tranche of $0.50 million was disbursed on December 3, 2024.
- Interest Rates: Notes accrue interest at 10.0% annually, increasing to 18% upon an event of default.
- Conversion Terms: Notes are convertible at the lower of $2.00 or 90% of the lowest daily VWAP during the preceding 10 trading days, subject to a floor price of $0.33.
- Ownership Limits: The Investor is restricted from beneficially owning more than 4.99% of outstanding shares unless shareholder approval is obtained for the "Exchange Cap" (19.99%).
- Fees: A $25,000 structuring fee was paid, with a $300,000 commitment fee payable in three tranches over 270 days.
Material Changes and Agreements
The primary material change is the execution of the SEPA and Convertible Notes on December 3, 2024. This agreement provides a flexible financing mechanism where the company can direct the purchase of shares at 97% of the lowest daily VWAP over three days. The agreement includes specific "Amortization Events" (e.g., stock price falling below the floor price for three days) that would trigger mandatory monthly payments of $150,000 plus a 10% premium and accrued interest to the Investor.
Outlook, Risks, and Contingencies
- Nasdaq Delisting Risk: On November 26, 2024, the company received notice that a previously disclosed delisting action has been stayed pending a final decision by a Nasdaq Hearing Panel. An oral hearing is scheduled for January 21, 2025. There is no assurance the appeal will be successful or that the company will remain listed.
- Liquidity Contingency: Proceeds from the SEPA and notes are intended for working capital and general corporate purposes. The company is not obligated to sell shares under the SEPA except in specific circumstances.
- Termination: The SEPA terminates on January 1, 2027, or upon the sale of $10 million in shares, whichever occurs first. The company may terminate the agreement with five trading days' notice if no advances are outstanding.
Investor Verification Checklist
- Verify the status of the Nasdaq delisting appeal scheduled for January 21, 2025.
- Confirm the effectiveness of the Registration Statement required for the resale of shares under the SEPA.
- Monitor the stock price relative to the $0.33 floor price to assess the risk of triggering mandatory amortization payments.
- Review the dilution impact of the $2.0 million convertible notes and potential future sales under the $10 million SEPA.
- Check for shareholder approval requirements regarding the 19.99% Exchange Cap.